clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Iris Diseases D007499 2 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Paul P et al. Capillary electrophoresis with capacitively coupled contactless conductivity detection method development and validation for the determination of azithromycin, clarithromycin, and clindamycin. 2017 J Sep Sci pmid:28683179
Morimoto K et al. A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. 2017 Ann Am Thorac Soc pmid:27788025
Wong AYS et al. Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. 2017 Drug Saf pmid:28397186
Baluch A et al. Successful management of Mycobacterium haemophilum lower extremity cutaneous infection in a matched-unrelated donor stem cell transplant recipient. 2017 Transpl Infect Dis pmid:27775824
Aziz DB et al. Rifabutin Is Active against Mycobacterium abscessus Complex. 2017 Antimicrob. Agents Chemother. pmid:28396540
Maruyama M et al. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Eradication: A Randomized Controlled Trial. 2017 Can J Gastroenterol Hepatol pmid:28349044
Brouqui P et al. Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB). 2017 Int. J. Antimicrob. Agents pmid:28336312
Xu YF et al. and Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection. 2017 Antimicrob. Agents Chemother. pmid:28320722
Yang YJ et al. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. 2017 Ann. Med. pmid:28266875
Yoon HY et al. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. 2017 Int. J. Tuberc. Lung Dis. pmid:28826448
Yoon H et al. Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis. 2017 Gut Liver pmid:27282269
Santos RP et al. induced rash and mucositis: a recently described entity. 2017 BMJ Case Rep pmid:28830900
Kwon S et al. [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Eradication]. 2017 Korean J Gastroenterol pmid:28830132
Nanishi E et al. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. 2017 J Am Heart Assoc pmid:28684643
Boal Carvalho P et al. Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting? 2017 Acta Med Port pmid:28550827
Shah SA et al. Clarithromycin inhibits TNF-α-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway. 2017 Int. Immunopharmacol. pmid:28550735
Jakubů V et al. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015. 2017 Cent. Eur. J. Public Health pmid:29346850
Vaz AM et al. Capsule endoscopy in the diagnosis of disseminated complex infection. 2017 BMJ Case Rep pmid:29167222
Lee H et al. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. 2017 Trials pmid:29149904
Fremlin GA et al. Clarithromycin, rifampicin and fusidic acid triple combination therapy for chronic folliculocentric pustulosis of the scalp. 2017 Clin. Exp. Dermatol. pmid:28691163
Andere NMRB et al. Clarithromycin as an Adjunct to One-Stage Full-Mouth Ultrasonic Periodontal Debridement in Generalized Aggressive Periodontitis: A Randomized Controlled Clinical Trial. 2017 J. Periodontol. pmid:28671507
Adachi T et al. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori. 2017 Oncology pmid:29258111
Moon SH et al. Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. 2017 J. Med. Chem. pmid:29136469
Feng L et al. Removal of antibiotics during the anaerobic digestion of pig manure. 2017 Sci. Total Environ. pmid:28628813
Freyne B and Curtis N Mycobacterium gordonae Skin Infection in an Immunocompetent Child. 2017 Pediatr. Infect. Dis. J. pmid:28403059
Bustamante-Rengifo JA et al. Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. 2017 World J. Gastroenterol. pmid:28373764
Marin AC et al. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. 2017 Drugs pmid:28361211
Holmberg LA et al. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. 2017 Acta Haematol. pmid:28355602
Smith S et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. 2017 Eur J Gastroenterol Hepatol pmid:28350745
Mougari F et al. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. 2017 J. Antimicrob. Chemother. pmid:28333340
Chen PY et al. Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28074519
Zamani M et al. Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. 2017 Aliment. Pharmacol. Ther. pmid:28074507
Chey WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. 2017 Am. J. Gastroenterol. pmid:28071659
Fernández Martos R et al. Acute psychotic episode secondary to Helicobacter pylori eradication treatment. 2017 Rev Esp Enferm Dig pmid:28071063
Ko J et al. Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review. 2017 Medicine (Baltimore) pmid:29390522
Takeuchi S et al. Hypotension induced by the concomitant use of a calcium-channel blocker and clarithromycin. 2017 BMJ Case Rep pmid:28069789
Vianna JS et al. The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori. 2018 Rev. Inst. Med. Trop. Sao Paulo pmid:29972462
Myojin S et al. Chronic otitis media caused by Mycobacterium abscessus spp. massiliense treated with tigecycline in a 10-year-old child. 2018 Int. J. Infect. Dis. pmid:29966711
Liou JM et al. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. 2018 Gastroenterology pmid:29964036
Kwofie SK et al. Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. 2018 Molecules pmid:29954088
Tanabe H et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. 2018 Ann. Clin. Microbiol. Antimicrob. pmid:29950163
Fiorini G et al. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. 2018 Eur J Gastroenterol Hepatol pmid:29481383
Talarico S et al. High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. 2018 Helicobacter pmid:29480566
Takemori N et al. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report. 2018 J Med Case Rep pmid:29454372
Zagari RM et al. Treatment of Helicobacter pylori infection: A clinical practice update. 2018 Eur. J. Clin. Invest. pmid:29144559
Liu DS et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. 2018 Clin. Microbiol. Infect. pmid:29138101
Redondo JJ et al. A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. 2018 Diagn. Microbiol. Infect. Dis. pmid:29111147
Iwamoto J et al. Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease. 2018 Intern. Med. pmid:29093413
Ullah S et al. Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability. 2018 Artif Cells Nanomed Biotechnol pmid:28541761
Cheung KS et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for : a population-based study. 2018 Gut pmid:29089382